Imagion Biosystems is now a publicly traded company after completing a heavily supported A$12 million initial public offering (IPO) on the Australian Securities Exchange. Imagion issued 60 million new shares as part of the IPO at A$0.20 per share, valuing the company at A$43 million upon listing.
The company’s shares trade under the symbol IBX on the Australian Securities Exchange. Download the official announcement.
The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required
